Navigation Links
Gene responsible for developing prostate cancer identified

Researchers from University of North Carolina have identified a molecule Ack1, which is responsible for suppressing the activity of Tumor// suppressor protein. Tumor suppressor protein is responsible for maintaining the integrity of cell and prevents the cell from developing tumor by maintaining a control growth of cell. Ack1 is found to be a growth promoting tyrosine kinase gene family. The results of the study has been published in the Journal Cancer research.

Tests of Ack1 demonstrate a profound effect on tumor growth in experimental systems, Earp said. 'It's a remarkable effect. Tumors grew more rapidly and invaded as if they were converted to advanced prostate cancer.'

Another major finding of the study involved an experimental drug developed by the National Cancer Institute, called geldanamycin. In laboratory tests, the UNC Lineberger group found Ack1 activity could be inhibited through interference with its molecular interactions, thus offering a target for treatment. First, the group discovered that Ack1 bound to a protein called Hsp90 (heat shock protein 90), which associated with many oncogenic, or cancer-causing, signaling proteins.

'If you add geldanamycin to the prostate cancer cell, the drug knocks Hsp90 off oncogenic signaling molecules. This dramatically decreases Ack1 activity and slows tumor formation,' Earp said.

In addition, the team compared Ack1 activation in advanced prostate cancer tissue from patients with that found in benign prostatic hypertrophy, or non-cancerous prostate enlargement. The team showed the levels of the activated Ack1 to be much higher in the advanced tumors.

'We saw that Mer was expressed at reasonably high levels in prostate cancer cells. And so Dr. Nupam Mahajan, the study's first author, decided to look at whether Mer had an effect on prostate cancer growth signaling,' Earp said. In experiments, which used the university's Michael Hooker Proteomics Core Facility, the team discovered that Mer activated Ack1. This finding led to the current study. 'Because we found Ack1 is more active in advanced prostate tumors, and its inhibition blocks experimental tumor growth, we believe Ack1 should be a target for novel drug development.'


'"/>




Related medicine news :

1. The right is responsible
2. Gene responsible for depression
3. Gene responsible for immune deficiency discovered
4. Genes responsible for social behavior of us
5. Molecule responsible for muscle repair identified
6. Genes responsible for cancer in women associated with increased cancer risk in men
7. Fixational eye movement responsible for visibility
8. Metal traces in infant formula cans responsible for recall.
9. Get that wedding ring on if you want to be branded a responsible parent!
10. Greater g factor in men responsible for sex differences in general mental ability
11. Molecule responsible for age associated macular degeneration identified
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... it has been selected by Tidelands Health, a three hospital system in South ... be constantly on the lookout for technology that enhances communication, drives workflow efficiencies ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its new pediatric ... practice tricky or rare procedures in an environment that looks and feels real. , ... available to inventors and “hackers” to develop and test new devices or software platforms ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people ... death across the United States and account for one death every four minutes. ... are permanently disabled. HCR ManorCare is launching a video series called “Your Brain,” in ...
(Date:5/3/2016)... Los Angeles, CA (PRWEB) , ... May 03, 2016 , ... ... Massage Chair with its user friendly Samsung tablet and exclusive Smart Application. The ... truly unbeatable massage. Starting each massage with a customized user profile and specialized massage ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... healthcare industry, announced today that Legacy Health is expanding its use of Intrigma’s ... after a highly successful initial proof of concept. The Portland, Oregon based health ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... 2, 2016 Kalorama Information noted the 5 ... market in a recent white paper.  The healthcare market ... usage, a growing market are among the top drivers ... report EMR 2016: The Market for Electronic ... complete study of the EMR industry, and the report ...
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... New Jersey , April 29, 2016 /PRNewswire/ ... Software Suite for Life Sciences, Product Development Capabilities ... Global Life Science Customer Base . ... solutions provider, today announced the acquisition of Skura ... a global leader in adaptive sales enablement technology ...
Breaking Medicine Technology: